Geoffrey Bergman

Geoffrey Bergman

Auto-generated profile, based on publicly available information

Geoffrey Bergman

Department of Medicine, Division of Cardiology, Weill Cornell Medicine – New York Presbyterian Hospital, Weill Cornell Cardiovascular Outcomes Research Group (CORG) and the Greenberg Institute for Cardiac Electrophysiology, NY (E.V.R., C.F.L., S.C.W., G.B., J.E.I., G.T., S.M.M., B.B.L., L.K.K., J.W.C.).

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The American Journal of Medicine
Verified
Journal Article
Closed access
UKUdhay Krishnan
Udhay Krishnan
JBJosef A. Brejt
Josef A. Brejt
JSJoshua Schulman-Marcus
Joshua Schulman-Marcus
RSRajesh V. Swaminathan
Rajesh V. Swaminathan
DFDmitriy N. Feldman
Dmitriy N. Feldman
LKLuke K. Kim
Luke K. Kim

1 June 2019 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
SWShing Chiu Wong
Shing Chiu Wong
IYIlhwan Yeo
Ilhwan Yeo
GBGeoffrey Bergman
Geoffrey Bergman
DFDmitriy N. Feldman
Dmitriy N. Feldman
HSHarsimran Sachdeva Singh
Harsimran Sachdeva Singh
LKLuke K. Kim
Luke K. Kim

1 February 2010 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DFDmitriy N. Feldman
Dmitriy N. Feldman
FFFoluso Fakorede
Foluso Fakorede
RMRobert M. Minutello
Robert M. Minutello
GBGeoffrey Bergman
Geoffrey Bergman
IMIssam D. Foundation Moussa
Issam D. Foundation Moussa
SWS. Chiu Wong
S. Chiu Wong

1 April 2023 in Stroke
Verified
Journal Article
Closed access
EKEdward V. Kogan
Edward V. Kogan
CSChristopher T. Sciria
Christopher T. Sciria
CLChristopher Liu
Christopher Liu
SWShing Chiu Wong
Shing Chiu Wong
GBGeoffrey Bergman
Geoffrey Bergman
JCJim W. Cheung
Jim W. Cheung
Background: Percutaneous endocardial left atrial appendage occlusion (LAAO) is an alternative therapy for stroke prevention in patients with atrial fibrillation who are poor candidates for oral anticoagulants. Oral anticoagulation is generally discontinued 45 days following successful LAAO. Real-world data on early stroke and mortality following LAAO are lacking. Methods: Using International Classification of Diseases, Tenth Revision , Clinical-Modification codes, we performed a retrospective observational registry analysis to examine the rates and predictors of stroke, mortality, and procedural complications during index hospitalization and 90-day readmission among 42 114 admissions in the Nationwide Readmissions Database for LAAO between 2016 and 2019. Early stroke and mortality were defined as events occurring during index admission or 90-day readmission. Data on timing of early strokes post-LAAO were collected. Multivariable logistic regression modeling was used to ascertain predictors of early stroke and major adverse events. Results: LAAO was associated with low rates of early stroke (0.63%), early mortality (0.53%), and procedural complications (2.59%). Among patients who had readmissions with strokes after LAAO, the median time from implant to readmission was 35 days (interquartile range, 9–57 days); 67% of readmissions with strokes occurred <45 days postimplant. Between 2016 and 2019, the rates of early stroke after LAAO significantly decreased (0.64% versus 0.46% P -for-trend <0.001), while early mortality and major adverse event rates were unchanged. Peripheral vascular disease and a history of prior stroke were independently associated with early stroke after LAAO. Early post-LAAO stroke rates were similar between low, medium, and high LAAO volume tertile centers. Conclusions: In this contemporary real-world analysis, the early stroke rate after LAAO was low, with the majority occurring within 45 days of device implantation. Despite an increase in LAAO procedures between 2016 and 2019, there with a significant decline in early strokes after LAAO during that period.

13 July 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
DSDiala Steitieh
Diala Steitieh
AZAlyssa Zaidi
Alyssa Zaidi
SXShirley Xu
Shirley Xu
JCJim W. Cheung
Jim W. Cheung
DFDmitriy N. Feldman
Dmitriy N. Feldman
LKLuke K. Kim
Luke K. Kim
Severe mitral regurgitation is a progressive disease associated with high morbidity and mortality, and frequent readmissions for heart failure. Surgical mitral valve repair or replacement has been the gold-standard treatment; however, advances in transcatheter edge-to-edge repair (TEER) have provided alternatives for high-risk surgical patients. There are no data on racial disparities in access to high-volume TEER centers. Data on TEER hospitalizations from New York, New Jersey, Maryland, North Carolina, Washington, Colorado, Arizona, and Florida were analyzed using the State Inpatient Databases for 2016. The baseline characteristics of patients who underwent TEER at high- (≥25 procedures per year) and low-volume centers were identified. The association between race and the likelihood of undergoing TEER at high-volume centers was assessed. The secondary outcomes were mortality and the frequency of home discharges. Of 1567 patients included in the analysis, 1129 underwent TEER at high-volume centers. Patients treated at high-volume centers had a higher prevalence of chronic kidney disease and congestive heart failure. Black and Hispanic patients were 59% (adjusted odds ratio [OR], 0.41; P < .001) and 51% (adjusted OR, 0.49; P < .001) less likely to undergo TEER at high-volume centers, respectively, compared with White patients. Hispanic patients were 3 times more likely to die during index admission than White patients (adjusted OR, 3.32; P = .027). There was geographic clustering of TEER centers, and a higher ratio of White patients to minority patients in zip codes with high-volume TEER centers. Racial minorities patients, particularly Black and Hispanic patients, are less likely to undergo TEER at high-volume centers. Hispanic patients experience higher rates of in-hospital mortality after TEER than White patients.

20 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SJSun-Joo Jang
Sun-Joo Jang
IYIlhwan Yeo
Ilhwan Yeo
CJChanel Jonas
Chanel Jonas
PGParag Goyal
Parag Goyal
JCJim W. Cheung
Jim W. Cheung
LKLuke K. Kim
Luke K. Kim
The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.